TREATMENT ADHERENCE OF SELUMETINIB AMONG PATIENTS DIAGNOSED WITH NEUROFIBROMATOSIS TYPE I AND PLEXIFORM NEUROFIBROMA IN THE UNITED STATES

Authors
Category Primary study
JournalNeuro-Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 551fc1f1de8dae3e7e4eab96c2762771a746c5d6
First added on: Feb 15, 2025